NO864276L - Gen som koder for produksjonen av pichia-argininsuccinatlyase. - Google Patents

Gen som koder for produksjonen av pichia-argininsuccinatlyase.

Info

Publication number: NO864276L
Authority: NO; Norway
Prior art keywords: dna; pichia; gene; plasmid; arginine
Prior art date: 1985-10-25

Application number

NO864276A

Other languages

English (en)

Norwegian (no)

Other versions

NO864276D0 (no

Inventor

James Michael Cregg

George T Sperl

Original Assignee

Phillips Petroleum Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-10-25

Filing date

1986-10-24

Publication date

1987-04-27

1986-10-24 Application filed by Phillips Petroleum Co filed Critical Phillips Petroleum Co

1986-10-24 Publication of NO864276D0 publication Critical patent/NO864276D0/no

1987-04-27 Publication of NO864276L publication Critical patent/NO864276L/no

Links

108090000623 proteins and genes Proteins 0.000 title claims description 24
238000004519 manufacturing process Methods 0.000 title claims description 17
108090000856 Lyases Proteins 0.000 title claims description 16
102000004317 Lyases Human genes 0.000 title claims description 15
210000004027 cell Anatomy 0.000 claims description 56
108020004414 DNA Proteins 0.000 claims description 54
239000013612 plasmid Substances 0.000 claims description 49
241000235648 Pichia Species 0.000 claims description 40
239000012634 fragment Substances 0.000 claims description 30
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 29
241000588724 Escherichia coli Species 0.000 claims description 26
241000235058 Komagataella pastoris Species 0.000 claims description 25
238000000034 method Methods 0.000 claims description 17
230000002950 deficient Effects 0.000 claims description 16
239000004475 Arginine Substances 0.000 claims description 13
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 13
230000000694 effects Effects 0.000 claims description 12
108090000765 processed proteins & peptides Proteins 0.000 claims description 11
102000004196 processed proteins & peptides Human genes 0.000 claims description 11
108020004511 Recombinant DNA Proteins 0.000 claims description 6
210000005253 yeast cell Anatomy 0.000 claims description 6
230000006696 biosynthetic metabolic pathway Effects 0.000 claims description 4
239000013611 chromosomal DNA Substances 0.000 claims description 4
239000003550 marker Substances 0.000 claims description 4
108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
235000015097 nutrients Nutrition 0.000 claims description 3
230000010076 replication Effects 0.000 claims description 3
108091008146 restriction endonucleases Proteins 0.000 claims description 3
241000894006 Bacteria Species 0.000 claims description 2
230000001105 regulatory effect Effects 0.000 claims description 2
239000000463 material Substances 0.000 claims 2
238000011084 recovery Methods 0.000 claims 2
108020005091 Replication Origin Proteins 0.000 claims 1
230000001580 bacterial effect Effects 0.000 claims 1
210000004748 cultured cell Anatomy 0.000 claims 1
102000004169 proteins and genes Human genes 0.000 claims 1
239000002609 medium Substances 0.000 description 35
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 27
101150005709 ARG4 gene Proteins 0.000 description 26
230000009466 transformation Effects 0.000 description 21
239000000243 solution Substances 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
229920001817 Agar Polymers 0.000 description 14
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
239000008272 agar Substances 0.000 description 14
239000008103 glucose Substances 0.000 description 13
239000000203 mixture Substances 0.000 description 13
239000000523 sample Substances 0.000 description 13
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 11
238000005119 centrifugation Methods 0.000 description 11
239000000600 sorbitol Substances 0.000 description 11
229920001184 polypeptide Polymers 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
238000002955 isolation Methods 0.000 description 9
239000000047 product Substances 0.000 description 9
230000008929 regeneration Effects 0.000 description 9
238000011069 regeneration method Methods 0.000 description 9
238000011534 incubation Methods 0.000 description 8
235000013343 vitamin Nutrition 0.000 description 8
239000011782 vitamin Substances 0.000 description 8
229940088594 vitamin Drugs 0.000 description 8
229930003231 vitamin Natural products 0.000 description 8
150000003722 vitamin derivatives Chemical class 0.000 description 8
235000001014 amino acid Nutrition 0.000 description 7
229940024606 amino acid Drugs 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 7
230000009469 supplementation Effects 0.000 description 7
230000001131 transforming effect Effects 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000002253 acid Substances 0.000 description 6
239000000284 extract Substances 0.000 description 6
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 6
239000013598 vector Substances 0.000 description 6
239000007984 Tris EDTA buffer Substances 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
239000008367 deionised water Substances 0.000 description 5
229910021641 deionized water Inorganic materials 0.000 description 5
230000029087 digestion Effects 0.000 description 5
238000009396 hybridization Methods 0.000 description 5
229910001868 water Inorganic materials 0.000 description 5
239000007222 ypd medium Substances 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
230000007547 defect Effects 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
229960000988 nystatin Drugs 0.000 description 4
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
BHKSYEZGBQDNRW-SCGRZTRASA-N C(CCC(=O)O)(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O Chemical compound C(CCC(=O)O)(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O BHKSYEZGBQDNRW-SCGRZTRASA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
241000364057 Peoria Species 0.000 description 3
241000235070 Saccharomyces Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
238000000855 fermentation Methods 0.000 description 3
230000004151 fermentation Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
244000005700 microbiome Species 0.000 description 3
230000000869 mutational effect Effects 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000008057 potassium phosphate buffer Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000000844 transformation Methods 0.000 description 3
102000004452 Arginase Human genes 0.000 description 2
108700024123 Arginases Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
108010001496 Galectin 2 Proteins 0.000 description 2
102100021735 Galectin-2 Human genes 0.000 description 2
108010033128 Glucan Endo-1,3-beta-D-Glucosidase Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
238000013019 agitation Methods 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000010804 cDNA synthesis Methods 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
238000010276 construction Methods 0.000 description 2
239000013068 control sample Substances 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
238000013507 mapping Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
238000011160 research Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000013605 shuttle vector Substances 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
108010082737 zymolyase Proteins 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
HMVYERAUBSAVAX-UHFFFAOYSA-N 1-nitro-1-nitrosoguanidine Chemical compound NC(=N)N(N=O)[N+]([O-])=O HMVYERAUBSAVAX-UHFFFAOYSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000178041 Ceropegia media Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
238000007399 DNA isolation Methods 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
239000006142 Luria-Bertani Agar Substances 0.000 description 1
229910021380 Manganese Chloride Inorganic materials 0.000 description 1
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
OHVGNSMTLSKTGN-BTVCFUMJSA-N [C].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound [C].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O OHVGNSMTLSKTGN-BTVCFUMJSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
244000309466 calf Species 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000007773 growth pattern Effects 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
229940094991 herring sperm dna Drugs 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
101150085823 hsdR gene Proteins 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000007689 inspection Methods 0.000 description 1
239000011565 manganese chloride Substances 0.000 description 1
235000002867 manganese chloride Nutrition 0.000 description 1
239000013028 medium composition Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
230000010627 oxidative phosphorylation Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
-1 polypropylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
239000004540 pour-on Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
230000001718 repressive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000002791 soaking Methods 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000004804 winding Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/848—Escherichia
- Y10S435/849—Escherichia coli
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
- Y10S435/938—Pichia

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)

NO864276A 1985-10-25 1986-10-24 Gen som koder for produksjonen av pichia-argininsuccinatlyase. NO864276L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/791,485 US4818700A (en)	1985-10-25	1985-10-25	Pichia pastoris argininosuccinate lyase gene and uses thereof

Publications (2)

Publication Number	Publication Date
NO864276D0 NO864276D0 (no)	1986-10-24
NO864276L true NO864276L (no)	1987-04-27

Family

ID=25153888

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO864276A NO864276L (no)	1985-10-25	1986-10-24	Gen som koder for produksjonen av pichia-argininsuccinatlyase.

Country Status (8)

Country	Link
US (1)	US4818700A (xx)
EP (1)	EP0221455A1 (xx)
JP (1)	JPS62107789A (xx)
AU (1)	AU587288B2 (xx)
DK (1)	DK510686A (xx)
IL (1)	IL80285A0 (xx)
MX (1)	MX7659E (xx)
NO (1)	NO864276L (xx)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5204252A (en) *	1989-02-08	1993-04-20	Henkel Research Corporation	Candida tropicalis transformation system
ES2080957T3 (es) *	1990-07-13	1996-02-16	Transkaryotic Therapies Inc	Metodo para escrutar una genoteca.
WO1992013951A1 (en) *	1991-02-04	1992-08-20	The Salk Institute Biotechnology/Industrial Associates, Inc.	Production of human serum albumin in methylotrophic yeast cells
US5866542A (en) *	1994-10-18	1999-02-02	Corvas International, Inc.	Nematode-extracted anticoagulant protein
WO1996012021A2 (en) *	1994-10-18	1996-04-25	Corvas International, Inc.	Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5866543A (en) *	1995-06-05	1999-02-02	Corvas International, Inc.	Nematode-extracted anticoagulant protein
US5863894A (en) *	1995-06-05	1999-01-26	Corvas International, Inc.	Nematode-extracted anticoagulant protein
US5945275A (en) *	1994-10-18	1999-08-31	Corvas International, Inc.	Nematode-extracted anticoagulant protein
CA2202351A1 (en) *	1994-10-18	1996-04-25	George Phillip Vlasuk	Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5872098A (en) *	1995-06-05	1999-02-16	Corvas International, Inc.	Nematode-extracted anticoagulant protein
MX9605082A (es)	1996-10-24	1998-04-30	Univ Autonoma De Nuevo Leon	Levaduras metilotroficas modificadas geneticamente para la produccion y secrecion de hormona de crecimiento humano.
JP2003507006A (ja) *	1999-05-20	2003-02-25	サイオス，インコーポレーテッド	血管内皮増殖因子改変体
JP2003500053A (ja) *	1999-05-20	2003-01-07	サイオス，インコーポレーテッド	血管内皮増殖因子ダイマー
US6440414B1 (en)	1999-10-01	2002-08-27	Amgen Inc.	Pharmaceutical compositions of fibrinolytic agent
US6261820B1 (en) *	1999-10-01	2001-07-17	Amgen Inc.	Fibronolytically active polypeptide
US7033776B2 (en) *	1999-12-17	2006-04-25	Amgen Inc.	Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
WO2001077366A1 (en) *	2000-04-10	2001-10-18	Cubist Pharmaceuticals, Inc.	Positive selection method, compounds, host cells and uses thereof
US7625756B2 (en)	2000-06-28	2009-12-01	GycoFi, Inc.	Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7598055B2 (en) *	2000-06-28	2009-10-06	Glycofi, Inc.	N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7863020B2 (en) *	2000-06-28	2011-01-04	Glycofi, Inc.	Production of sialylated N-glycans in lower eukaryotes
US8697394B2 (en) *	2000-06-28	2014-04-15	Glycofi, Inc.	Production of modified glycoproteins having multiple antennary structures
US7029872B2 (en)	2000-06-28	2006-04-18	Glycofi, Inc	Methods for producing modified glycoproteins
US7449308B2 (en)	2000-06-28	2008-11-11	Glycofi, Inc.	Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
DK1294910T3 (da)	2000-06-30	2009-03-02	Vib Vzw	Protein glykosyleringsmodifikation i Pichia Pastoris
EP2022799A2 (en)	2001-11-16	2009-02-11	Biogen Idec Inc.	Polycistronic expression of antibodies
IL165717A0 (en)	2002-06-26	2006-01-15	Flanders Interuniversity Inst	A strain of methylotrophic yeast for producing proteins
DE60335602D1 (de) *	2002-12-18	2011-02-17	Roche Diagnostics Gmbh	Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
ATE387494T1 (de) *	2002-12-20	2008-03-15	Hoffmann La Roche	Hitzelabile desoxyribonuklease i-varianten
US7332299B2 (en) *	2003-02-20	2008-02-19	Glycofi, Inc.	Endomannosidases in the modification of glycoproteins in eukaryotes
EP1460425A1 (en) *	2003-03-17	2004-09-22	Boehringer Mannheim Gmbh	Deglycosylated enzymes for conjugates
ES2337684T3 (es) *	2003-12-05	2010-04-28	F. Hoffmann-La Roche Ag	Carboxipeptidasa b recombinante y su purificacion.
US7588745B2 (en) *	2004-04-13	2009-09-15	Si Options, Llc	Silicon-containing products
AU2006291780B2 (en) *	2005-09-14	2011-12-08	F. Hoffmann-La Roche Ag	Cleavage of precursors of insulins by a variant of trypsin
EP2027271A4 (en) *	2006-05-19	2010-06-09	Glycofi Inc	RECOMBINANT VECTORS
EP3078743B1 (en)	2007-09-28	2020-06-24	Portola Pharmaceuticals, Inc.	Antidotes for factor xa inhibitors and methods of using the same
US8067339B2 (en)	2008-07-09	2011-11-29	Merck Sharp & Dohme Corp.	Surface display of whole antibodies in eukaryotes
EP2324121B1 (en)	2008-08-12	2012-11-07	GlycoFi, Inc.	Improved vectors and yeast strains for protein production: ca2+ atpase overexpression
BR122012024318A2 (pt)	2008-09-26	2019-07-30	Ambrx, Inc.	Polipeptídeos modificados de eritropoetina animal e seus usos
FI3604510T3 (fi)	2009-03-30	2025-06-26	Alexion Pharma Inc	Vastalääkkeitä tekijä xa:n estäjille ja menetelmiä niiden käyttämiseksi
WO2011008885A1 (en)	2009-07-15	2011-01-20	Portola Pharmaceuticals, Inc.	Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
AU2010307098A1 (en)	2009-10-16	2012-04-26	Merck Sharp & Dohme Corp.	Method for producing proteins in Pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
US20130011875A1 (en)	2009-10-30	2013-01-10	Merck Sharpe & Dohme Corp	Methods for the production of recombinant proteins with improved secretion efficiencies
KR101930961B1 (ko)	2010-02-24	2018-12-19	머크 샤프 앤드 돔 코포레이션	피키아 파스토리스에서 생산된 치료 당단백질 상의 ｎ-글리코실화 부위 점유를 증가시키는 방법
JP6193220B2 (ja)	2011-05-20	2017-09-06	アルダーバイオ・ホールディングズ・エルエルシー	形質転換されたピキア・パストリス（Ｐｉｃｈｉａｐａｓｔｏｒｉｓ）などの微生物における抗体などのマルチサブユニットタンパク質の高純度生産
KR101978534B1 (ko)	2011-08-19	2019-08-28	앨더바이오 홀딩스 엘엘씨	변형된 미생물 이를 테면 피치아 파스토리스(pichia pastoris)에서 다수의 아단위 단백질들, 이를 테면 항체의 고역가 및 고순도 생산을 위한 다중-복사체 전략
US20130230901A1 (en)	2012-02-14	2013-09-05	Portola Pharmaceuticals, Inc.	Process for making recombinant antidote to factor xa inhibitor
JP6735561B2 (ja)	2012-12-03	2020-08-05	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
US9944689B2 (en)	2013-03-07	2018-04-17	The General Hospital Corporation	Human CTLA4 mutants and use thereof
CA2905180C (en)	2013-03-15	2023-03-07	Alder Biopharmaceuticals, Inc.	Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
CA2905531C (en)	2013-03-15	2023-01-03	Alder Biopharmaceuticals, Inc.	Antibody purification and purity monitoring
CA2917912C (en)	2013-07-24	2019-09-17	Streck, Inc.	Compositions and methods for stabilizing circulating tumor cells
US11168351B2 (en)	2015-03-05	2021-11-09	Streck, Inc.	Stabilization of nucleic acids in urine
WO2017011275A1 (en)	2015-07-10	2017-01-19	Nersissian Aram M	Factor viii protein compositions and methods of treating hemophilia a
HUE069884T2 (hu)	2015-10-09	2025-04-28	Genzyme Corp	Javított flare (áramlási citometriával csillapított reporter expresszió) technológia gyors tömeges válogatáshoz
US20170145475A1 (en)	2015-11-20	2017-05-25	Streck, Inc.	Single spin process for blood plasma separation and plasma composition including preservative
US11506655B2 (en)	2016-07-29	2022-11-22	Streck, Inc.	Suspension composition for hematology analysis control
TWI795373B (zh)	2016-10-07	2023-03-11	美商健臻公司	用於生物製劑生產之細胞早期轉染後分離（ｅｐｉｃ）
EP3697209B1 (en)	2017-10-19	2024-07-24	Streck LLC	Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles
EP3505181B1 (en)	2017-12-28	2021-07-07	Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center	Preparation of enzyme replacement therapy for mucopolysaccharidosis iiid
US12421316B2 (en)	2019-02-19	2025-09-23	The Regents Of The University Of Colorado, A Body Corporate	Bispecific immunotoxins targeting human CD25+CCR4+ tumors and regulatory T-cells
FI4010379T3 (fi)	2019-08-08	2025-06-26	Alexion Pharma Inc	Koostumuksia ja menetelmiä tekijä XA:n ja johdannaisten valmistamiseksi
NL2031833B1 (en)	2022-05-11	2023-11-17	Univ Leiden	Immunotherapeutic compositions and adjuvants
WO2024032891A1 (en)	2022-08-11	2024-02-15	Vib Vzw	Glyco-engineered yeast for therapeutic protein production
WO2025196308A1 (en)	2024-03-22	2025-09-25	Vib Vzw	Means and methods for displaying fc-containing proteins on cells and selection thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4617274A (en) *	1981-10-29	1986-10-14	Phillips Petroleum Company	Biochemical conversions by yeast fermentation at high cell densities
US4879231A (en) *	1984-10-30	1989-11-07	Phillips Petroleum Company	Transformation of yeasts of the genus pichia
US4837148A (en) *	1984-10-30	1989-06-06	Phillips Petroleum Company	Autonomous replication sequences for yeast strains of the genus pichia
US4855231A (en) *	1984-10-30	1989-08-08	Phillips Petroleum Company	Regulatory region for heterologous gene expression in yeast

1985
- 1985-10-25 US US06/791,485 patent/US4818700A/en not_active Expired - Lifetime
1986
- 1986-10-08 MX MX86972U patent/MX7659E/es unknown
- 1986-10-10 IL IL80285A patent/IL80285A0/xx unknown
- 1986-10-14 AU AU63881/86A patent/AU587288B2/en not_active Ceased
- 1986-10-20 JP JP61249404A patent/JPS62107789A/ja active Pending
- 1986-10-23 EP EP86114699A patent/EP0221455A1/en not_active Withdrawn
- 1986-10-24 DK DK510686A patent/DK510686A/da not_active Application Discontinuation
- 1986-10-24 NO NO864276A patent/NO864276L/no unknown

Also Published As

Publication number	Publication date
IL80285A0 (en)	1987-01-30
EP0221455A1 (en)	1987-05-13
NO864276D0 (no)	1986-10-24
DK510686D0 (da)	1986-10-24
DK510686A (da)	1987-04-26
JPS62107789A (ja)	1987-05-19
MX7659E (es)	1990-06-19
AU587288B2 (en)	1989-08-10
AU6388186A (en)	1987-04-30
US4818700A (en)	1989-04-04

Publication	Publication Date	Title
NO864276L (no)	1987-04-27	Gen som koder for produksjonen av pichia-argininsuccinatlyase.
NO854333L (no)	1986-05-02	Isolering av gener fra gjaerarter av slekten pichia.
CA1273882A (en)	1990-09-11	Autonomous replication sequences for yeast strains of the genus pichia
EP0560401B1 (en)	2000-12-06	DNA fragment encoding an AOX
US4666847A (en)	1987-05-19	Recombinant DNA means and method
CA1297438C (en)	1992-03-17	Transformation of yeasts of the genus pichia
JP2003159090A (ja)	2003-06-03	ピキア（Ｐｉｃｈｉａ）蛋白質分解活性に影響する遺伝子およびその使用
US4826763A (en)	1989-05-02	Process for preparing glucagon or fragments or derivatives thereof in yeast
JP2001500003A (ja)	2001-01-09	タンパク質の過剰発現
US5135868A (en)	1992-08-04	Cultures of yeast of the genus Pichia altered by site selective genomic modification
Conway et al.	1987	Gene expression in Zymomonas mobilis: promoter structure and identification of membrane anchor sequences forming functional lacZ'fusion proteins
US4977085A (en)	1990-12-11	Cloning and expression of yeast STE13 and Dpp2 genes encoding dipeptidyl aminopeptidase A and B
US5496711A (en)	1996-03-05	Processes for producing pre-prorennin, prorennin and rennin
NO891485L (no)	1989-10-12	Fremgangsmaate til fremstilling av 22 kd sgh-protein og lineaer genevektor.
Beltzer	1988	Yeast LEU4: One gene, two proteins, and multiple controls
IE83234B1 (en)	2004-01-14	DNA fragment encoding an AOX